Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
P. Comella, G. Comella(Tumour Institute of Tuscany), L. Maiorino, Vito Lorusso(Istituto Tumori Bari), A Mangiameli, G.P. Nicolella(Radiation Oncology Institute), N. Panza, E Micillo(Medical Center Hospital), Alfredo Lamberti(Medical Center Hospital), R Cioffi(Medical Center Hospital), Francovito Piantedosi(Ospedale Monaldi), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M. De Lena(Istituto Tumori Bari), G. Frasci(Radiation Oncology Institute)
Cited by 16
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
|Lung Cancer|2019|158
Lapatinib in breast cancer
|Annals of Oncology|2007|129